When is AMLX's latest earnings report released?
The most recent financial report for Amylyx pharmaceuticals, inc. (AMLX) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating AMLX's short-term business performance and financial health. For the latest updates on AMLX's earnings releases, visit this page regularly.
How is AMLX's revenue growth?
In the latest financial report, Amylyx pharmaceuticals, inc. (AMLX) announced revenue of 0, with a Year-Over-Year growth rate of -100%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
How much debt does AMLX have?
As of the end of the reporting period, Amylyx pharmaceuticals, inc. (AMLX) had total debt of 5.94M, with a debt ratio of 0.02. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
How much cash does AMLX have?
At the end of the period, Amylyx pharmaceuticals, inc. (AMLX) held Total Cash and Cash Equivalents of 226.16M, accounting for 0.62 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Is AMLX's EPS continuing to grow?
According to the past four quarterly reports, Amylyx pharmaceuticals, inc. (AMLX)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.37. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of AMLX?
Amylyx pharmaceuticals, inc. (AMLX)'s Free Cash Flow (FCF) for the period is -30.39M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 26.86% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
What are the PEG ratio and PE ratio of AMLX?
The latest valuation data shows Amylyx pharmaceuticals, inc. (AMLX) has a Price-To-Earnings (PE) ratio of -9.17 and a Price/Earnings-To-Growth (PEG) ratio of 0.47. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.
